S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains

Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

$107.10
-1.80 (-1.65%)
(As of 04/17/2024 ET)

Jazz Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$195.08
82.15% Upside
High Forecast$230.00
Average Forecast$195.08
Low Forecast$131.00
TypeCurrent Forecast
4/19/23 to 4/18/24
1 Month Ago
3/20/23 to 3/19/24
3 Months Ago
1/19/23 to 1/19/24
1 Year Ago
4/19/22 to 4/19/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
7 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$195.08$193.91$191.56$204.27
Predicted Upside82.15% Upside57.28% Upside48.96% Upside35.35% Upside
Get Jazz Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

JAZZ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Jazz Pharmaceuticals Stock vs. The Competition

TypeJazz PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.85
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside82.15% Upside934.64% Upside12.25% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/10/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$180.00+59.33%
3/22/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$170.00 ➝ $190.00+55.94%
3/20/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$200.00+60.88%
3/20/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$220.00+76.00%
3/20/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$171.00 ➝ $188.00+50.40%
3/15/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$225.00 ➝ $230.00+87.04%
3/14/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$204.00 ➝ $200.00+62.59%
3/1/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$135.00 ➝ $131.00+9.71%
3/1/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$235.00 ➝ $230.00+92.61%
2/29/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$195.00+63.60%
1/3/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$160.00+26.05%
9/28/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
8/10/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$204.00 ➝ $217.00+60.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:00 AM ET.

JAZZ Price Target - Frequently Asked Questions

What is Jazz Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Jazz Pharmaceuticals stock is Moderate Buy based on the current 2 hold ratings and 11 buy ratings for JAZZ. The average twelve-month price prediction for Jazz Pharmaceuticals is $195.08 with a high price target of $230.00 and a low price target of $131.00. Learn more on JAZZ's analyst rating history.

Do Wall Street analysts like Jazz Pharmaceuticals more than its competitors?

Analysts like Jazz Pharmaceuticals more than other Medical companies. The consensus rating score for Jazz Pharmaceuticals is 2.85 while the average consensus rating score for medical companies is 2.68. Learn more on how JAZZ compares to other companies.

Does Jazz Pharmaceuticals's stock price have much upside?

According to analysts, Jazz Pharmaceuticals's stock has a predicted upside of 58.71% based on their 12-month stock forecasts.

What analysts cover Jazz Pharmaceuticals?

Stock Ratings Reports and Tools

This page (NASDAQ:JAZZ) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners